AbbVie licenses Nxera's oral EP4 agonist NXE0033744 for IBD in a $100M upfront global deal. Read the key terms and what this ...

Novo Nordisk Q3 2026 earnings show CagriSema outperforming tirzepatide in weight loss. Explore the full pipeline update, ...

A2 Biotherapeutics' MSLN-targeting A2B694 CAR T therapy produced a 12-month-plus complete response in one NSCLC patient. Read ...

AstraZeneca withdraws its EU application for Truqap in PTEN-deficient prostate cancer after a CHMP provisional opinion. Read ...

Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up ...

AN2 Therapeutics receives FDA IND clearance for epetraborole in polycythemia vera, completing approvals in Australia, India ...

Servier's sevasemten missed its Phase III GRAND CANYON primary endpoint in Becker muscular dystrophy. Read how these results ...

Pfizer Q3 2026 earnings: second positive Elrexfio Phase III readout, atirmociclib tolerability data and mevrometostat delay.

Camurus has dosed the first patient in LUNAR-2, a Phase IIb study of monthly semaglutide depot CAM2056 for obesity. Explore ...

Ensem registers a Phase I/II trial of oral pan-KRAS inhibitor ETX-929 for KRAS-altered solid tumors. Learn how it's tested ...

Columbia researchers show deleting certain sugar transport genes helps E. coli colonize tumors better. Learn how this could ...

Thryv Therapeutics secures $30M Series B to launch the ASPIRE-HF heart failure study of its SGK1 inhibitor. Read how this ...